Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19

NCT ID: NCT05007522

Last Updated: 2024-06-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-05-03
• Study Completion Date: 2024-06-20

Brief Summary

The purpose of this study is to evaluate the safety and effectiveness of ketotifen and indomethacin taken together to improve symptoms related with COVID-19. Ketotifen and indomethacin are medications approved by the Food and Drug Administration (FDA) to treat diseases other than COVID-19. Their use in this study is investigational, meaning they have not been approved by the FDA to treat COVID-19.

Detailed Description

Coronavirus Disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which is a recently emerged coronavirus that has resulted in an ongoing global pandemic. Fever and cough are most commonly experienced at disease presentation and complications involving the vascular system also occur as potential manifestations of severe disease. In human autopsy studies, infiltration of mononuclear cells in the lung tissue concurrent with edema and hemorrhage are frequently noted5. Other than lung epithelial cells, infection is also observed in endothelial cells, possibly augmenting endothelial activation and vascular permeability6. It is believed that lung pathology during COVID-19 is immune-mediated and compounded by the infiltration of monocytes, neutrophils and subsets of T cells7. Interestingly, perturbations in the numbers of granulocytes in the blood, such as neutrophils and eosinophils have also been shown to be associated with severe disease1, 8, 9.

Mast cells (MCs) are long-lived granulated immune cells that are present in both connective and mucosal tissues10. Our data in animal models support that MCs are strongly activated during infection by SARS-CoV-2 virus. Animal studies suggested that drugs in the class of MC "stabilizers" can effectively limit vascular leakage in mouse models of viral infection, such as caused by dengue virus (DENV).

Ketotifen is an oral drug currently used to prevent asthma. It is used to treat irritation and reduce vascular leakage, such as in the eye. It is a MC stabilizing agent that prevents degranulation of MCs, as well as the production of additional mediators that are not contained within MC granules, including leukotrienes and platelet activating factor 32. Indomethacin is an inhibitor of cyclooxygenase (COX) 1 and 2 receptors and, therefore, its primary mechanism of action is through inhibition of prostaglandin synthesis. It is used to treat inflammatory disorders and pain including rheumatoid arthritis, tendinitis, gout, and nephrogenic diabetes insipidus due to its antipyretic and analgesic properties.

This is a randomized, double blind, placebo-controlled, clinical study of ketotifen and indomethacin in adults 18 to 75 years of age, who meet at least two symptoms indicating COVID-19 infection, and who test positive for COVID-19 infection by a PCR based assay or rapid detection assay. Patients meeting all inclusion and exclusion criteria will be enrolled. Eligible patients who present at or are referred to trial sites will undergo screening. Trained research staff will obtain informed consent from participants. Patients meeting all inclusion and exclusion criteria and who agree to participate will be enrolled for the duration of the study.The study will be conducted as an outpatient study. One hundred and fifty (150) patients will be randomized 2:1 to ketotifen/indomethacin or placebo.

The primary objectives is as follows:

To evaluate the safety ketotifen and indomethacin, in combination, in COVID-19 patients.

Hypothesis: This drug combination will be safe in COVID-19 patients, with no increase in adverse events, and no increased severity of COVID-19 disease. (clinical endpoint)

To investigate the effectiveness of ketotifen and indomethacin for improving clinical measures of respiratory function and/or resolution of COVID-19 symptoms.

Hypothesis: Combination treatment of COVID-19 patients with ketotifen and indomethacin will improve patient measures of shortness of breath and/or promote the resolution of COVID-19 respiratory symptoms, shortening the duration of those symptoms. (clinical endpoint)

Conditions

COVID-19 Respiratory Infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Study Drug

Ketotifen 2 mg administered in tablet form twice a day (every 12 hr). Indomethacin sustained-release (SR) 75 mg, twice a day (every 12 hr). Patients will be administered 28 doses in total of ketotifen/indomethacin combination.

Group Type: EXPERIMENTAL

Ketotifen/Indomethacin

Intervention Type: DRUG

2 mg tablet, 75 mg SR tablet

Placebo

Placebo pills matching in appearance to study drug twice a day for 28 doses total.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Matching placebo tablet

Interventions

Ketotifen/Indomethacin

2 mg tablet, 75 mg SR tablet

Intervention Type: DRUG

Placebo

Matching placebo tablet

Intervention Type: DRUG

Other Intervention Names

Zaditor; Indocin SR; Tivorbex

Eligibility Criteria

Inclusion Criteria

1. Adult patients aged 18-75 years

2. Has SARS-CoV-2-positive antigen or molecular diagnostic test (validated SARS-CoV-2 antigen, RT-PCR, or other molecular diagnostic assay from a sample collected no more than 7 days prior to enrollment.

3. At least two signs or symptoms of disease consistent with acute COVID-19 infection. One of these two symptoms must include cough OR shortness of breath with onset within 7 days prior to randomization. Other symptoms that qualify include:

1. Fever

2. nausea

3. vomiting

4. diarrhea

5. muscle aches

6. fatigue

7. headache

8. loss of smell or taste

9. others that are consistent with acute COVID-19 infection in the opinion of the Investigator.

4. Able and willing to give written or oral informed consent

5. Willing to be an outpatient from Study Day 1 to 14, to provide blood during patient visits on Study Days 1, 3, 5, and 10, return on Study Days 1, 3, 5, 7, 10, 14, and 21 for assessment.

6. Willing to keep a diary of pain medication usage, side effects, and COVID-19 associated symptoms and answer a follow-up questionnaire on Study Day 84.

Exclusion Criteria

1. Clinical signs and symptoms for severe COVID-19, such as:

1. Need for hospitalization at the time of screening

2. Need for supplemental O2 at the time of screening

2. A person with any of the following laboratory values:

1. AST or ALT >/= 1000 U/L

2. Known serum creatinine > 1.6 mg/dL

3. Prior use of any of the following treatments: COVID-19 convalescent plasma, monoclonal antibodies against SARS-CoV-2, IVIG (for COVID-19), or COVID-19 treatments (authorized, approved, or investigational)

4. Current usage (within the last 7 days prior to randomization) of any of the following drugs:

1. anticoagulant drugs including, but not limited to, aspirin, warfarin, or clopidogrel.

2. systemic corticosteroids or non-steroidal anti-inflammatory medications for any indication

3. drugs that are known to block the functions of ketotifen, such as propranolol.

4. oral anti-diabetic agents

5. diflunisal or other drugs (or drugs at certain doses) that are contraindicated for concurrent use with Indomethacin

5. Prior vaccination of at least one dose of vaccine for SARS-CoV-2

6. Has participated, is participating, or plans to participate in a clinical research study evaluating any authorized, approved, or investigational drug SARS-CoV-2

7. Any other clinically significant acute illness within 7 days prior to first study drug administration that would impact outcome assessment.

8. Patients with a history of any gastrointestinal bleeding requiring medical care.

9. Exposure to any new investigational agent within 30 days prior to the study drug administration.

10. Clinically significant abnormal physical examination unrelated to COVID-19 infection that would impact outcome assessment.

11. Females who are pregnant or breast feeding.

12. Current significant medical condition or illness including cardiac arrhythmias, cardiomyopathy or other cardiac disease, advanced renal disease, immunocompromised state including known HIV infection, or any other illness that the Investigator considers should exclude the patient, especially those that require continuation of other medications likely to have an interaction with the study drug. Patients with a history of allergy will not be excluded unless the allergy may be directed to the Study Drug, other NSAIDs, or other tablet ingredient.

13. Any condition that would render the informed consent invalid, or limit the ability of the patient to comply with the study requirements.

14. Inability to comply with completing the outcome assessment measure(s).

15. Any condition that, in the opinion of the investigator, would complicate or compromise the study or well-being of the patient.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National University of Singapore

OTHER

Sponsor Role: collaborator

Sen-Jam Pharmaceutical

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alexander T Limkakeng, MD

Role: PRINCIPAL_INVESTIGATOR

Duke University

Locations

Dhulikhel Hospital

Kavre, Bagmati, Nepal

Global Clinical Research Pvt. Ltd.

Kathmandu, , Nepal

Countries

Nepal

References

St John AL, Rathore APS. Early Insights into Immune Responses during COVID-19. J Immunol. 2020 Aug 1;205(3):555-564. doi: 10.4049/jimmunol.2000526. Epub 2020 Jun 8.

Reference Type: BACKGROUND

PMID: 32513850 (View on PubMed)

Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol. 2010 Jun;10(6):440-52. doi: 10.1038/nri2782.

Reference Type: BACKGROUND

PMID: 20498670 (View on PubMed)

St John AL, Abraham SN. Innate immunity and its regulation by mast cells. J Immunol. 2013 May 1;190(9):4458-63. doi: 10.4049/jimmunol.1203420.

Reference Type: BACKGROUND

PMID: 23606723 (View on PubMed)

Rathore AP, St John AL. Protective and pathogenic roles for mast cells during viral infections. Curr Opin Immunol. 2020 Oct;66:74-81. doi: 10.1016/j.coi.2020.05.003. Epub 2020 Jun 18.

Reference Type: BACKGROUND

PMID: 32563779 (View on PubMed)

Kiani P, Scholey A, Dahl TA, McMann L, Iversen JM, Verster JC. In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2. Viruses. 2021 Mar 26;13(4):558. doi: 10.3390/v13040558.

Reference Type: BACKGROUND

PMID: 33810356 (View on PubMed)

Other Identifiers

Pro00108924

Identifier Type: -

Identifier Source: org_study_id